Polygenic Score (PGS) ID: PGS000160

Predicted Trait
Reported Trait Prostate cancer
Mapped Trait(s) prostate carcinoma (EFO_0001663)
Released in PGS Catalog: April 29, 2020
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name cGRS_Prostate
Development Method
Name Pruning and Thresholding (P+T)
Parameters GWAS significant and r2 < 0.2. PGS levels were computed as product(dosage*weight/expected risk effect), where the expected risk effect for each variant was calculated based on the risk allele frequence (f) and risk allele weight (OR) as f^2*OR^2 + 2f(1-f)OR + (1-f)^2.
Variants
Original Genome Build NR
Number of Variants 79
Effect Weight Type Odds Ratio over expected risk
PGS Source
PGS Catalog Publication (PGP) ID PGP000075
Citation (link to publication) Shi Z et al. Cancer Med (2019)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 91.5%
African: 3.8%
East Asian: 3%
Hispanic or Latin American: 1.7%
337,424 individuals (100%)
PGS Evaluation
European: 100%
1 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST000017
Europe PMC: 17401363
 2,329 individuals European NR
—
[
  • 212 cases
  • , 1,313 controls
]
,
100.0 % Male samples
 European 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
GWAS Catalog: GCST006085
Europe PMC: 29892016
 140,254 individuals European NR
GWAS Catalog: GCST001942
Europe PMC: 23535732
 22,548 individuals European NR
GWAS Catalog: GCST002606
Europe PMC: 25217961
 2,080 individuals Hispanic or Latin American NR
GWAS Catalog: GCST002606
Europe PMC: 25217961
 6,954 individuals East Asian NR
GWAS Catalog: GCST002606
Europe PMC: 25217961
 10,463 individuals Sub-Saharan African, African American or Afro-Caribbean NR
GWAS Catalog: GCST002606
Europe PMC: 25217961
 67,543 individuals European NR
GWAS Catalog: GCST002944
Europe PMC: 26034056
 3,226 individuals East Asian CMHS, GERA, ProHealth, RPGEH
GWAS Catalog: GCST002944
Europe PMC: 26034056
 2,251 individuals African American or Afro-Caribbean CMHS, GERA, ProHealth, RPGEH
GWAS Catalog: GCST002944
Europe PMC: 26034056
 3,629 individuals Hispanic or Latin American CMHS, GERA, ProHealth, RPGEH
GWAS Catalog: GCST002944
Europe PMC: 26034056
 37,272 individuals European CMHS, GERA, ProHealth, RPGEH
GWAS Catalog: GCST000489
Europe PMC: 19767754
 37,350 individuals European ICR, IGD, deCODE

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000491 PSS000280|
European Ancestry|
6,828 individuals
 PGP000075 |
Shi Z et al. Cancer Med (2019)
 Reported Trait: Prostate cancer — — Odds Ratio (OR; high vs. average risk groups): 1.73 [1.38, 2.17] — —
PPM000480 PSS000280|
European Ancestry|
6,828 individuals
 PGP000075 |
Shi Z et al. Cancer Med (2019)
 Reported Trait: Prostate cancer — — Mean realative risk: 1.3 [1.21, 1.38]
Wilcoxon test (case vs. control) p-value: 2.07e-18		 — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000280 — —
[
  • 0 cases
  • , 6,407 controls
]
,
100.0 % Male samples
 — European — eMERGE —
PSS000280 Primary tumor samples from TCGA —
[
  • 421 cases
  • , 0 controls
]
,
100.0 % Male samples
 Mean = 62.0 years
Sd = 7.0 years		 European — TCGA —